RxDoctor Payments Data

Viviane Santos Sachs, MD

Family Medicine · Tulsa, OKNPI 1720428451

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 13 payments — averaging $101.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$603
  • Pulmonx Corporation$147
  • Novartis$124
  • Bayer$122
  • Boehringer Ingelheim$122
  • GSK$97
  • plus $99 from 2 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$22,564
Medicare patients
106
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$34,216
TrulicityDulaglutide21$33,069
JardianceEmpagliflozin27$28,471
EliquisApixaban25$23,311
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,203
Albuterol Sulfate HfaAlbuterol Sulfate43$1,053
Gabapentin57$733
Omeprazole25$657
Rosuvastatin Calcium16$593
Atorvastatin Calcium100$591
Fluticasone Propionate19$533
Lisinopril74$465
Amlodipine Besylate75$395
Chlorthalidone17$360
Metformin Hcl52$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$78$33,06921 claims
Boehringer IngelheimJardiance$122$28,47127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →